Screening method based on siah-numb interaction
OwnerRobert Amson, Adam Telerman +1inventors
InventorsRobert Amson, Adam Telerman, Moshe Oren
Life of this patent
Estimating the term…
Abstract
This invention encompasses methods of screening the compounds that are involved in the regulation of tumor suppression and apoptosis based on the interaction between Siah and Numb proteins.
Claims22
Process for identifying a compound which inhibits the binding of Siah to Numb, characterized in that it exhibits the steps of:
- a) bringing the said compound into contact with a mammalian cell which is expressing the Siah and Numb proteins;
- b) identifying the increase in the quantity of Numb protein in the said mammalian cell as compared with a control cell with which the said compound has not been brought into contact.
Process for identifying a compound which inhibits the binding of Siah to Numb, which process exhibits the steps of:
- a) bringing the said compound into contact with a system which enables the binding between Siah and Numb to be determined in vitro;
- b) identifying the decrease in and/or inhibition of the binding between Siah and Numb.
Process for identifying a compound for increasing tumour suppression and/or cell death (apoptosis), characterized in that it exhibits the steps of:
- a) bringing the said compound into contact with a mammalian cell which is expressing the Siah and Numb proteins;
- b) identifying the decrease in the quantity of Numb protein in the said mammalian cell as compared with a control cell with which the said compound has not been brought into contact.
Process for identifying a compound for decreasing and/or inhibiting tumour suppression and/or cell death (apoptosis), which process exhibits the steps of:
- a) bringing compounds into contact with a system which enables the binding between Siah and Numb to be determined in vitro;
- b) identifying the compounds which induce a decrease in and/or inhibition of the binding between Siah and Numb;
- c) bringing the compounds identified in step b) into contact with a mammalian cell which is expressing the Siah and Numb proteins;
- d) identifying the increase in the quantity of Numb protein in the said mammalian cell as compared with a control cell with which the said compound has not been brought into contact.
Process for identifying a region of Siah which is active in increasing tumour suppression and/or apoptosis, comprising the steps of:
- a) bringing peptides derived from the Siah protein into contact with a mammalian cell which is expressing the Numb protein;
- b) identifying the decrease in the quantity of Numb protein in the said mammalian cell by comparison with the quantity of Numb protein which is present in a control mammalian cell which is expressing the Siah and Numb proteins.
Process for identifying a region of Siah which is active in decreasing and/or inhibiting tumour suppression and/or apoptosis, comprising the steps of:
- a) bringing peptides derived from the Siah protein into contact with a mammalian cell which is expressing the Numb protein;
- b) identifying the increase in the quantity of Numb protein in the said mammalian cell by comparison with the quantity of Numb protein which is present in a control mammalian cell which is expressing the Siah and Numb proteins.
Process for identifying the regions of Siah which are involved in the binding with the Numb protein, comprising the steps of:
- a) bringing peptides derived from the Siah protein into contact in a system which enables the binding between Siah and Numb to be determined in vitro;
- b) identifying the peptides which bring about the decrease in the binding between Siah and Numb in the said system.
Complex which consists of a Siah protein and a Numb protein.
Dependencies are inferred from the claim text.